Azithromycin and COVID-19: Prompt early use at first signs of this infection in adults and children, an approach worthy of consideration.
Identifieur interne : 001854 ( Main/Exploration ); précédent : 001853; suivant : 001855Azithromycin and COVID-19: Prompt early use at first signs of this infection in adults and children, an approach worthy of consideration.
Auteurs : Robert A. Schwartz [États-Unis] ; Robert M. Suskind [États-Unis]Source :
- Dermatologic therapy [ 1529-8019 ] ; 2020.
Descripteurs français
- KwdFr :
- Adulte (MeSH), Antibactériens (usage thérapeutique), Azithromycine (usage thérapeutique), Betacoronavirus (MeSH), Enfant (MeSH), Humains (MeSH), Infections à coronavirus (traitement médicamenteux), Infections à coronavirus (épidémiologie), Pandémies (MeSH), Pneumopathie virale (traitement médicamenteux), Pneumopathie virale (épidémiologie), Relation dose-effet des médicaments (MeSH).
- MESH :
- traitement médicamenteux : Infections à coronavirus, Pneumopathie virale.
- usage thérapeutique : Antibactériens, Azithromycine.
- épidémiologie : Infections à coronavirus, Pneumopathie virale.
- Adulte, Betacoronavirus, Enfant, Humains, Pandémies, Relation dose-effet des médicaments.
English descriptors
- KwdEn :
- Adult (MeSH), Anti-Bacterial Agents (therapeutic use), Azithromycin (therapeutic use), Betacoronavirus (MeSH), COVID-19 (MeSH), Child (MeSH), Coronavirus Infections (drug therapy), Coronavirus Infections (epidemiology), Dose-Response Relationship, Drug (MeSH), Humans (MeSH), Pandemics (MeSH), Pneumonia, Viral (drug therapy), Pneumonia, Viral (epidemiology), SARS-CoV-2 (MeSH).
- MESH :
- chemical , therapeutic use : Anti-Bacterial Agents, Azithromycin.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- epidemiology : Coronavirus Infections, Pneumonia, Viral.
- Adult, Betacoronavirus, COVID-19, Child, Dose-Response Relationship, Drug, Humans, Pandemics, SARS-CoV-2.
Abstract
The devastating effects of the coronavirus designated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have led to urgent attempts to find effective therapeutic agents for inpatient and outpatient treatment of COVID-19. Initial enthusiasm for the combination of hydroxychloroquine and azithromycin has abated. However, as a result of positive clinical experience with azithromycin used alone during the first few days of the flu-like illness caused by this coronavirus, we recommend formal clinical trials using azithromycin early in the course of a COVID-19 infection. There is one clinical trial initiated, the individually randomized, telemedicine-based, "Azithromycin for COVID-19 Treatment in Outpatients Nationwide" based at the University of California San Francisco. This placebo-controlled trial is designed to determine the efficacy of a single 1.2-g dose of oral azithromycin to prevent COVID-19 patient progression to hospitalization. We recommend formal clinical trials of azithromycin in its prepackaged form at the first sign of COVID-19 infection in adults and children, using an initial adult dose of 500 mg followed by 250 mg per day for 4 days, a total cumulative dose of 1.5 g, and for children 5 to 18 years of age, 10 mg/kg on the first day followed by 5 mg/kg for 4 days.
DOI: 10.1111/dth.13785
PubMed: 32510734
PubMed Central: PMC7300563
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Azithromycin and COVID-19: Prompt early use at first signs of this infection in adults and children, an approach worthy of consideration.</title><author><name sortKey="Schwartz, Robert A" sort="Schwartz, Robert A" uniqKey="Schwartz R" first="Robert A" last="Schwartz">Robert A. Schwartz</name><affiliation wicri:level="1"><nlm:affiliation>Professor of Dermatology and Pathology, Rutgers University New Jersey Medical School, Newark, New Jersy, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Professor of Dermatology and Pathology, Rutgers University New Jersey Medical School, Newark, New Jersy</wicri:regionArea><wicri:noRegion>New Jersy</wicri:noRegion></affiliation></author><author><name sortKey="Suskind, Robert M" sort="Suskind, Robert M" uniqKey="Suskind R" first="Robert M" last="Suskind">Robert M. Suskind</name><affiliation wicri:level="2"><nlm:affiliation>Professor of Pediatrics and Founding Dean Emeritus, California University of Science of Medicine, San Bernardino, California, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Professor of Pediatrics and Founding Dean Emeritus, California University of Science of Medicine, San Bernardino, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32510734</idno><idno type="pmid">32510734</idno><idno type="doi">10.1111/dth.13785</idno><idno type="pmc">PMC7300563</idno><idno type="wicri:Area/Main/Corpus">001471</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001471</idno><idno type="wicri:Area/Main/Curation">001471</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001471</idno><idno type="wicri:Area/Main/Exploration">001471</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Azithromycin and COVID-19: Prompt early use at first signs of this infection in adults and children, an approach worthy of consideration.</title><author><name sortKey="Schwartz, Robert A" sort="Schwartz, Robert A" uniqKey="Schwartz R" first="Robert A" last="Schwartz">Robert A. Schwartz</name><affiliation wicri:level="1"><nlm:affiliation>Professor of Dermatology and Pathology, Rutgers University New Jersey Medical School, Newark, New Jersy, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Professor of Dermatology and Pathology, Rutgers University New Jersey Medical School, Newark, New Jersy</wicri:regionArea><wicri:noRegion>New Jersy</wicri:noRegion></affiliation></author><author><name sortKey="Suskind, Robert M" sort="Suskind, Robert M" uniqKey="Suskind R" first="Robert M" last="Suskind">Robert M. Suskind</name><affiliation wicri:level="2"><nlm:affiliation>Professor of Pediatrics and Founding Dean Emeritus, California University of Science of Medicine, San Bernardino, California, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Professor of Pediatrics and Founding Dean Emeritus, California University of Science of Medicine, San Bernardino, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author></analytic><series><title level="j">Dermatologic therapy</title><idno type="eISSN">1529-8019</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term><term>Anti-Bacterial Agents (therapeutic use)</term><term>Azithromycin (therapeutic use)</term><term>Betacoronavirus (MeSH)</term><term>COVID-19 (MeSH)</term><term>Child (MeSH)</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (epidemiology)</term><term>Dose-Response Relationship, Drug (MeSH)</term><term>Humans (MeSH)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (drug therapy)</term><term>Pneumonia, Viral (epidemiology)</term><term>SARS-CoV-2 (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte (MeSH)</term><term>Antibactériens (usage thérapeutique)</term><term>Azithromycine (usage thérapeutique)</term><term>Betacoronavirus (MeSH)</term><term>Enfant (MeSH)</term><term>Humains (MeSH)</term><term>Infections à coronavirus (traitement médicamenteux)</term><term>Infections à coronavirus (épidémiologie)</term><term>Pandémies (MeSH)</term><term>Pneumopathie virale (traitement médicamenteux)</term><term>Pneumopathie virale (épidémiologie)</term><term>Relation dose-effet des médicaments (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Bacterial Agents</term><term>Azithromycin</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antibactériens</term><term>Azithromycine</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Betacoronavirus</term><term>COVID-19</term><term>Child</term><term>Dose-Response Relationship, Drug</term><term>Humans</term><term>Pandemics</term><term>SARS-CoV-2</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Betacoronavirus</term><term>Enfant</term><term>Humains</term><term>Pandémies</term><term>Relation dose-effet des médicaments</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The devastating effects of the coronavirus designated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have led to urgent attempts to find effective therapeutic agents for inpatient and outpatient treatment of COVID-19. Initial enthusiasm for the combination of hydroxychloroquine and azithromycin has abated. However, as a result of positive clinical experience with azithromycin used alone during the first few days of the flu-like illness caused by this coronavirus, we recommend formal clinical trials using azithromycin early in the course of a COVID-19 infection. There is one clinical trial initiated, the individually randomized, telemedicine-based, "Azithromycin for COVID-19 Treatment in Outpatients Nationwide" based at the University of California San Francisco. This placebo-controlled trial is designed to determine the efficacy of a single 1.2-g dose of oral azithromycin to prevent COVID-19 patient progression to hospitalization. We recommend formal clinical trials of azithromycin in its prepackaged form at the first sign of COVID-19 infection in adults and children, using an initial adult dose of 500 mg followed by 250 mg per day for 4 days, a total cumulative dose of 1.5 g, and for children 5 to 18 years of age, 10 mg/kg on the first day followed by 5 mg/kg for 4 days.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32510734</PMID><DateCompleted><Year>2020</Year><Month>12</Month><Day>01</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1529-8019</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>4</Issue><PubDate><Year>2020</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Dermatologic therapy</Title><ISOAbbreviation>Dermatol Ther</ISOAbbreviation></Journal><ArticleTitle>Azithromycin and COVID-19: Prompt early use at first signs of this infection in adults and children, an approach worthy of consideration.</ArticleTitle><Pagination><MedlinePgn>e13785</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/dth.13785</ELocationID><Abstract><AbstractText>The devastating effects of the coronavirus designated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have led to urgent attempts to find effective therapeutic agents for inpatient and outpatient treatment of COVID-19. Initial enthusiasm for the combination of hydroxychloroquine and azithromycin has abated. However, as a result of positive clinical experience with azithromycin used alone during the first few days of the flu-like illness caused by this coronavirus, we recommend formal clinical trials using azithromycin early in the course of a COVID-19 infection. There is one clinical trial initiated, the individually randomized, telemedicine-based, "Azithromycin for COVID-19 Treatment in Outpatients Nationwide" based at the University of California San Francisco. This placebo-controlled trial is designed to determine the efficacy of a single 1.2-g dose of oral azithromycin to prevent COVID-19 patient progression to hospitalization. We recommend formal clinical trials of azithromycin in its prepackaged form at the first sign of COVID-19 infection in adults and children, using an initial adult dose of 500 mg followed by 250 mg per day for 4 days, a total cumulative dose of 1.5 g, and for children 5 to 18 years of age, 10 mg/kg on the first day followed by 5 mg/kg for 4 days.</AbstractText><CopyrightInformation>© 2020 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schwartz</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials><Identifier Source="ORCID">https://orcid.org/0000-0003-3036-3825</Identifier><AffiliationInfo><Affiliation>Professor of Dermatology and Pathology, Rutgers University New Jersey Medical School, Newark, New Jersy, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suskind</LastName><ForeName>Robert M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Professor of Pediatrics and Founding Dean Emeritus, California University of Science of Medicine, San Bernardino, California, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dermatol Ther</MedlineTA><NlmUniqueID>9700070</NlmUniqueID><ISSNLinking>1396-0296</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>83905-01-5</RegistryNumber><NameOfSubstance UI="D017963">Azithromycin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017963" MajorTopicYN="N">Azithromycin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">azithromycin</Keyword><Keyword MajorTopicYN="N">hydroxychloroquine</Keyword><Keyword MajorTopicYN="N">macrolide</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>05</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>06</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>06</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32510734</ArticleId><ArticleId IdType="doi">10.1111/dth.13785</ArticleId><ArticleId IdType="pmc">PMC7300563</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;105949:105949. https://doi.org/10.1016/j.ijantimicag.2020.105949.</Citation></Reference><Reference><Citation>Million M, Lagier JC, Gautret P, et al. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: a retrospective analysis of 1061 cases in Marseille, France. Travel Med Infect Dis. 2020;35:101738. https://doi.org/10.1016/j.tmaid.2020.101738.</Citation></Reference><Reference><Citation>Mahase E. Hydroxychloroquine for covid-19: the end of the line? BMJ. 2020;369:m2378. https://doi.org/10.1136/bmj.m2378.PMID:32540958.</Citation></Reference><Reference><Citation>Schwartz RA, Janniger CK. Generalized pustular figurate erythema. A newly delineated severe cutaneous drug reaction linked with hydroxychloroquine. Dermatol Ther. 2020;33(3):e13380. https://doi.org/10.1111/dth.13380.</Citation></Reference><Reference><Citation>Asensio E, Acunzo R, Uribe W, Saad EB, Sáenz LC. Recommendations for the measurement of the QT interval during the use of drugs for COVID-19 infection treatment. Updatable in accordance with the availability of new evidence. J Interv Card Electrophysiol. 2020;16:1-16. https://doi.org/10.1007/s10840-020-00765-3.</Citation></Reference><Reference><Citation>Gbinigie K, Frie K. Should azithromycin be used to treat COVID-19? A rapid review. BJGP Open. 2020. https://doi.org/10.3399/bjgpopen20X101094.</Citation></Reference><Reference><Citation>Tran DH, Sugamata R, Hirose T, et al. Azithromycin, a 15-membered macrolide antibiotic, inhibits influenza A(H1N1)pdm09 virus infection by interfering with virus internalization process. J Antibiot (Tokyo). 2019;72(10):759-768.</Citation></Reference><Reference><Citation>Retallack H, Di LE, Arias C, et al. Zika virus cell tropism in the developing human brain and inhibition by azithromycin. Proc Natl Acad Sci USA. 2016;113:14408-14413.</Citation></Reference><Reference><Citation>Bosseboeuf E, Aubry M, Nhan T, et al. Azithromycin inhibits the replication of Zika virus. J Antivir Antiretrovir. 2018;10:6-11.</Citation></Reference><Reference><Citation>Gérard A, Romani S, Fresse A, et al. French network of pharmacovigilance centers. “Off-label” use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: a survey of cardiac adverse drug reactions by the French network of pharmacovigilance centers. Therapies. 2020;32418730. https://doi.org/10.1016/j.therap.2020.05.002.</Citation></Reference><Reference><Citation>ClinicalTrials.gov. Azithromycin for COVID-19 Treatment in Outpatients Nationwide (ACTION). https://clinicaltrials.gov/ct2/show/NCT04332107</Citation></Reference><Reference><Citation>ClinicalTrials.gov. https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=Azithromycin&cntry=US&state=&city=&dist=</Citation></Reference><Reference><Citation>Almutairi N, Schwartz RA. COVID-19 with dermatologic manifestations and implications: an unfolding conundrum. Dermatol Ther May 9, 2020:e13544. doi: https://doi.org/10.1111/dth.13544. 32385869</Citation></Reference><Reference><Citation>Schwartz RA, Kapila R: Cutaneous manifestations of a 21st century worldwide fungal epidemic possibly complicating the COVID-19 pandemic to jointly menace mankind. Dermatol Ther May 5, 2020:e13481. doi: https://doi.org/10.1111/dth.13481. 32369240</Citation></Reference><Reference><Citation>Carlton PK Jr, Johanigman J, Janniger EJ, Schwartz RA. COVID-19 and the urgent need to render spaces safer. Global Policy. 2020;11(2). https://www.globalpolicyjournal.com/blog/15/05/2020/covid-19-and-urgent-need-render-spaces-safer.</Citation></Reference><Reference><Citation>Fan BE, Lim KGE, Chong VCL, Chan SSW, Ong KH, Kuperan P. COVID-19 and mycoplasma pneumoniae coinfection. Am J Hematol. 2020;95:723-724.</Citation></Reference><Reference><Citation>Gupta M, Abdelmaksoud A, Jafferany M, Lotti T, Sadoughifar R, Goldust M. COVID-19 and economy. Dermatol Ther. 2020;26:e13329. https://doi.org/10.1111/dth.13329.</Citation></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Californie</li></region></list><tree><country name="États-Unis"><noRegion><name sortKey="Schwartz, Robert A" sort="Schwartz, Robert A" uniqKey="Schwartz R" first="Robert A" last="Schwartz">Robert A. Schwartz</name></noRegion><name sortKey="Suskind, Robert M" sort="Suskind, Robert M" uniqKey="Suskind R" first="Robert M" last="Suskind">Robert M. Suskind</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001854 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001854 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32510734
|texte= Azithromycin and COVID-19: Prompt early use at first signs of this infection in adults and children, an approach worthy of consideration.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32510734" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |